Date:3/23/2010

925,489 Other long-term assets and deferred costs 308,973 257,623 Goodwill 2,348,453 2,502,909 --------- --------- Total assets $34,065,014 $56,391,270 =========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY ------------------------------------ Current liabilities: Accounts payable $1,934,119 $3,870,871 Accrued expenses and other liabilities 11,532,101 14,624,757 Convertible notes - 13,377,505 Current portion of long- term debt - 4,000,000 --------- --------- Total current liabilities 13,466,220 35,873,133 Other long-term liabilities 452,618 626,581 Derivative instruments 835,299 Convertible notes and other debt, net of discount of $2,705,440 in 2009 17,426,513 928,117 ---------- ------- Total liabilities 32,180,650 37,427,831 ---------- ---------- Stockholders' equity: Common stock, $0.0001 par value; 100,000,000 shares authorized; 28,130,284 and 25,890,143 shares issued and outstanding at December 31, 2009 and 2008 2,813 2,589 Additional paid-in- capital 157,004,037 142,392,163
'/>"/>

SOURCE PharmAthene, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
2. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
3. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
6. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
7. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
8. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
9. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
10. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
11. PharmAthene Reports Second Quarter 2009 Financial and Operational Results